Drug intelligence / Profile preview

WXSH0493

Development stage: Unknown
Lead developer: Lianyungang Kanion
Modality: Small Molecules
Administration: Oral

Overview

WXSH0493 is an investigational small molecule URAT1 inhibitor developed by Jiangsu Kanion Pharmaceutical for the management of hyperuricemia and gout. It targets the Solute Carrier Family 22 Member 12 (URAT1) transporter located on the apical membrane of proximal renal tubule cells. By inhibiting URAT1-mediated reabsorption of uric acid, WXSH0493 enhances uricosuric activity, leading to a reduction in serum uric acid levels. The compound is currently undergoing Phase 1 clinical evaluation to assess its safety, tolerability, and pharmacokinetics in healthy volunteers and patients with hyperuricemia.

Targets

URAT1 (Uric Acid Transporter 1)

Beyond the preview

Go deeper on WXSH0493.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WXSH0493.

Explore the full profile